The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 26th 2024
The top 5 most-read chronic obstructive pulmonary disease (COPD) articles of 2024 covered topics such as inhaled medication risks, gabapentinoid use, and the link between high white blood cell counts and exacerbations.
Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL
October 6th 2023Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.
Read More
FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer
October 6th 2023The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
Read More
First Tocilizumab Biosimilar Approved in the United States
October 5th 2023The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Read More
Alcohol Use Not Associated With Lower Odds of Achieving SVR With Hepatitis C Treatment
October 4th 2023The researchers noted that their findings suggest clinicians and policy makers should encourage hepatitis C virus (HCV) treatment in those with unhealthy alcohol consumption or alcohol use disorder (AUD) rather than create barriers to it.
Read More
Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC
October 4th 2023Following discussions with FDA, Takeda will voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) based on the outcomes of the phase 3 EXCLAIM-2 trial.
Read More
Scientists Whose Work on mRNA Allowed Development of COVID-19 Vaccines Win Nobel Prize
October 2nd 2023Katalin Karikó, PhD, and Drew Weissman, MD, PhD, were cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."
Read More